Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

A series of recent changes could have significant implications for how Americans receive and pay for their shots.

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in young children.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

South Africa has played a historic, global role in scientific research, from COVID-19 vaccines to HIV. Now that's under threat after the Trump administration cut hundreds of millions of dollars ...

Moderna MRNA announced that the FDA has approved its supplemental biologics license application seeking approval for COVID-19 vaccine, Spikevax, for use in children aged six months to 11 years, who ...

Pfizer's COVID vaccine (Comirnaty) is fully approved for patients ages 12 and up, and authorized for kids ages 6 months through 11 years. Novavax's COVID shot (Nuvaxovid) is fully approved for people ...

Republican leaders in the House are sprinting toward a vote on President Donald Trump’s tax and spending cuts package, determined to seize momentum from a hard-fought vote in the Senate ...